NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS)
| Market Cap | 2.47B-34.6% |
| Revenue (ttm) | 7.12M-88.9% |
| Net Income | -259.50M-56.6% |
| EPS | -2.18-32.1% |
| Shares Out | 116.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 393,976.349 |
| Open | 22.00 |
| Previous Close | 22.13 |
| Day's Range | 21.09 - 22.00 |
| 52-Week Range | 16.79 - 42.21 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 51.33(+142.87%) |
| Earnings Date | Nov 4, 2026 |
NewAmsterdam Pharma Co N.V. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NAMS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NAMS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NAMS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NAMS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NAMS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NAMS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NAMS
| ETF | Est. Holding Size |
|---|---|
| CGMMCapital Group U.S. Small and Mid Cap ETF | $16.81M |
| IBBiShares Biotechnology ETF | $12.94M |
| VHTVanguard Health Care ETF | $4.98M |
| SBIOALPS Medical Breakthroughs ETF | $3.36M |
| FSMOFidelity Fundamental Small-Mid Cap ETF | $1.31M |
| FFSMFidelity Fundamental Small-Mid Cap ETF | $1.31M |
Estimated from each fund’s disclosed top holdings × AUM
NAMS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NAMS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score